Israel Biotech Fund

Israel Biotech Fund focuses on building the future of Israeli biotech by identifying and maximizing the success of therapeutic assets from Israel-based biotech companies. Located in Rehovot, Israel's main biotech hub, the fund exclusively invests in biotech companies developing drugs at or near clinical stages. Partners include two top-tier international pharmaceutical companies, institutional investors, family offices, and high net worth individuals. Their unique asset is a team of 25 Venture Advisors, composed of renowned industry leaders and professionals who provide portfolio companies with hands-on guidance and support. Beyond investment, they offer the ability, experience, and network to identify the best opportunities and help portfolio companies achieve long-term success. The fund provides necessary resources for sustainable growth, enhancing company value and investors' long-term capital appreciation while strengthening Israel's biotech industry to increase investment opportunities. They are committed to realizing the enormous potential of Israel's growing biotechnology industry. The team includes General Partners David Sidransky, M.D., Yuval Cabilly, Ph.D., and Ido Zairi as co-founders, while their key Venture Advisors include Sol Barer, Ph.D. (former Chairman and CEO of Celgene), Jeff Kindler (former Chairman & CEO of Pfizer), Robert Spiegel, MD (former Chief Medical Officer of Schering-Plough), and Murray A. Goldberg (former CFO of Regeneron).